| Literature DB >> 16759990 |
Nicolas A van Larebeke1, Marc E Bracke, Vera Nelen, Gudrun Koppen, Greet Schoeters, Herman Van Loon, Robert Vlietinck.
Abstract
We measured tumor-associated proteins (TAPs) and pollutants in blood, serum, and urine of 200 nonsmoking women 50-65 years of age, residing in the rural municipality of Peer or in Hoboken or Wilrijk, industrial suburbs of Antwerp, Belgium. Persons with occupational exposures or commuting to other towns were excluded. Residents from Hoboken had significantly higher levels of blood lead and serum zinc and polychlorinated biphenyls. Surprisingly, residents of Peer had significantly higher levels of serum cadmium, dioxin-like activity in blood fat, and urinary 1-hydroxypyrene. For 5 of the 12 TAPs assessed in this study, we observed significant differences in serum levels among residents of the three municipalities after adjusting for personal or lifestyle parameters. Although we found levels of internal exposure to pollutants to be quite homogeneous in Flanders, we found significantly higher levels of TAPs only in the industrial suburbs. In multiple regression with all 29 available personal, lifestyle, and internal exposure parameters, blood lead levels showed a positive association with serum levels of anti-p53, carcino-embryonic antigen (CEA), and tissue polypeptide-specific antigen (TPS) and with an index for mean TAP level (I(tap)); dioxin-like activity in serum and serum copper showed a positive association with serum CA 125 (cancer antigen 125); and serum zinc showed a positive association with serum levels of c-erbB-2 ectodomain and TPS. An index of internal exposure showed a positive association with serum levels of both CEA and anti-p53 and with I(tap). This study provides some evidence that levels of internal exposure such as those present in Flanders, in particular concerning lead, are indeed associated with biologic effects.Entities:
Mesh:
Substances:
Year: 2006 PMID: 16759990 PMCID: PMC1480514 DOI: 10.1289/ehp.8811
Source DB: PubMed Journal: Environ Health Perspect ISSN: 0091-6765 Impact factor: 9.031
Internal exposure concentrations in blood, serum, and urine.
| Wilrijk | Hoboken | Peer | ||
|---|---|---|---|---|
| Blood or serum concentration | ||||
| Cadmium (nmol/L) | 5.34 (3.56–11.21)* | 5.34 (3.56–10.23)** | 6.23 (3.56–11.57) | 0.0097 |
| Copper (μmol/L) | 20.4 (15.1–26.6) | 19.8 (16.3–25.4) | 19.3 (16.5–25.8) | 0.56 |
| Lead (nmol/l) | 154.4 (71.4–229.7)## | 183.4 (108.6–337.8)**,## | 152.0 (84.5–255.8) | 0.0029 |
| Zinc (μmol/L) | 9.64 (8.17–10.89)### | 10.40 (9.26–12.47)***,### | 9.49 (7.65–11.41) | < 0.0001 |
| Dioxin-like activity (pg TEQ/g blood fat) | 30.8 (5.1–71.8)** | 41.9 (6.4–81.3) | 44.2 (16.6–80.3) | 0.010 |
| ∑PCBs (ng/g blood fat) | 379 (230–621)# | 459 (270–675)***,# | 370 (238–604) | 0.0006 |
| Selenium (μmol/L) | 1.26 (1.04–1.53)*** | 1.21 (0.96–1.52)*** | 1.10 (0.88–1.31) | < 0.0001 |
| Vitamin A (μmol/L) | 2.06 (1.45–2.94) | 2.06 (1.62–2.95)** | 1.85 (1.43–2.57) | 0.036 |
| Vitamin E (μmol/L) | 30.5 (23.2–38.6) | 32.6 (25.5–46.7) | 32.5 (25.6–45.9) | 0.093 |
| Concentration in urine | ||||
| Cadmium (nmol/mmol creatinine) | 0.73 (0.40–1.70) | 0.74 (0.45–1.59) | 0.97 (0.44–1.87) | 0.43 |
| 1-Hydroxypyrene (pmol/mmol creatinine) | 46.1 (7.5–92.9) | 38.0 (16.6–84.9)* | 49.0 (15.1–191.3) | 0.026 |
Values shown are median (10th–90th percentile).
Significant differences by Mann-Whitney U test between urban areas and Peer (*p ≤0.05, **p ≤0.01, and ***p ≤0.001), and between both urban areas (#p ≤0.05, ##p ≤0.01, and ###p ≤0.00).
Kruskal-Wallis test for differences between areas; if correction for multiple testing is implemented, statistical significance requires p < 0.0063.
Levels of TAPs: crude data.
| TAP | Wilrijk | Hoboken | Peer ( | Normal values | Residence ANCOVA |
|---|---|---|---|---|---|
| Anti-p53 (index) | 0.318 (0.050–0.589) | 0.464 (0.050–1.078) | 0.433 (0.073–0.755) | 0.0–1.1 | 0.16 |
| c-erbB-2 (pmol/mL) | 2.34 (1.73–2.82)# | 2.46 (1.56–3.65)*,# | 2.34 (1.72–2.82) | NA | 0.020 |
| TPS (U/L) | 31.0 (20.4–40.8)# | 34.0 (18.0–80.5)# | 31.0 (21.0–55.8) | 0–80 | 0.14 |
| AFP (ng/mL) | 1.50 (0.80–2.96) | 1.55 (1.00–3.05) | 1.60 (1.10–3.46) | 0–20 | 0.37 |
| CEA (ng/mL) | 0.30 (0.30–1.58) | 0.60 (0.30–2.45) | 0.60 (0.30–1.60) | 0–3.5 | 0.51 |
| CA 15-3 (U/mL) | 16.8 (11.8–25.1) | 16.1 (9.4–28.2) | 16.4 (10.2–25.6) | 0–38 | 0.46 |
| CA 125 (U/mL) | 13.1 (5.7–25.5) | 10.2 (5.6–25.1) | 12.4 (5.9–31.0) | 0–29 | 0.60 |
| hPLAP (mU/L) | 1.60 (0.10–28.96)# | 14.75 (0.10–37.55)# | 8.20 (0.10–29.95) | 0–100 | 0.14 |
| BTA (U/mL) | 9.20 (1.72–31.52)***,## | 3.50 (0.65–17.89)## | 3.20 (0.65–18.50) | 0–14 | 0.0001 |
| IGF-I (ng/mL) | 139 (88–260) | 148 (91–241) | 168 (102–231) | 91–443 | 0.27 |
| sIL-2R (U/mL) | 385 (120–617) | 344 (120–630) | 385 (172–670) | 85–961 | 0.26 |
| PDGF-BB (pg/mL) | 3,340 (1,792–5,532)***,# | 2,550 (1,070–4,780)**,# | 2,060 (280–3,534) | 942–7,366 | < 0.0001 |
NA, not available. Values shown are median (10th–90th percentile).
Significant differences by Fisher’s PLSD test on crude data, between urban areas and Peer (*p < 0.01, **p < 0.0045, and ***p < 0.0001), and between Wilrijk and Hoboken (#p < 0.05, and ##p < 0.0045).
If correction for multiple testing is implemented, statistical significance requires p ≤0.0045.
As established by the manufacturer of the measuring kit and controlled on a sample of the Flemish population.
Mean levels of TAPs adjusted for personal characteristics and lifestyle factors.
| TAP | Wilrijk | Hoboken | Peer ( | Residence ANCOVA |
|---|---|---|---|---|
| Anti-p53 (index) | 0.258 | 0.364 | 0.338 | 0.27 |
| c-erbB-2 (pmol/mL) | 2.36# | 2.49*,# | 2.28 | 0.098 |
| TPS (U/L) | 28.7# | 38.9# | 34.3 | 0.055 |
| AFP (ng/mL) | 1.59 | 1.63 | 1.78 | 0.51 |
| CEA (ng/mL) | 0.61 | 0.86 | 0.74 | 0.30 |
| CA 15-3 (U/mL) | 17.3 | 16.2 | 16.8 | 0.70 |
| CA 125 (U/mL) | 12.3 | 11.5 | 11.9 | 0.89 |
| hPLAP (mU/L) | 3.99# | 11.12# | 7.56 | 0.046 |
| BTA (U/mL) | 8.55**,## | 3.54## | 1.07 | 0.0008 |
| IGF-I (ng/mL) | 141 | 149 | 163 | 0.17 |
| sIL-2R (U/mL) | 364 | 331 | 352 | 0.75 |
| PDGF-BB (pg/mL) | 3,256**,# | 2,587*,# | 1,752 | < 0.0001 |
Values shown are adjusted geometric means after correction through ANCOVA analysis for age; BMI; level of education; smoking status; total number of pregnancies; total number of months of breast-feeding; serum levels of total fat, total cholesterol, triglycerides, selenium, vitamin A, and vitamin E; and all available food-intake parameters except those related to consumption of locally grown food (in total, 21 independent variables). Correction through ANCOVA analysis for only the most relevant potential confounding factors (age, level of education, smoking status, and parameters selected for each TAP through forward stepwise regression) gave similar results, with differences concerning c-erbB-2, hPLAP, BTA, and PDGF-BB statistically significant in ANCOVA (data not shown).
Significant differences in a Fisher’s PLSD test after correction for the above-mentioned 21 covariates, between urban areas and Peer (*p < 0.0045, and **p < 0.0001), and between Wilrijk and Hoboken (#p < 0.05, and ##p < 0.0045).
If correction for multiple testing is implemented, statistical significance requires p ≤0.0045.
Associations in multiple regression between levels of TAPs and parameters of internal exposure.
| TAP | Parameter of internal exposure | Regression coefficient | Standardized regression coefficient (95% CI) | Squared semipartial correlation | |
|---|---|---|---|---|---|
| Anti-p53 (index) | 0.35 | 0.23 (0.073–0.40) | 0.041 | 0.0050 | |
| Square root of CEA (ng/mL) | 0.16 | 0.19 (0.033–0.35) | 0.027 | 0.019 | |
| Anti-p53 (index) | Blood lead (nmol/L) | 0.0030 | 0.37 (0.21–0.52) | 0.10 | < 0.0001 |
| CEA (ng/mL) | Blood lead (nmol/L) | 0.0021 | 0.18 (0.03–0.34) | 0.026 | 0.019 |
| TPS (U/L) | Blood lead (nmol/L) | 0.107 | 0.22 (0.07–0.37) | 0.036 | 0.0055 |
| Blood lead (nmol/L) | 0.001 | 0.29 | 0.063 | 0.00046 | |
| c-erbB-2 (pmol/mL) | Serum zinc (μmol/L) | 0.072 | 0.19 (0.04–0.34) | 0.024 | 0.015 |
| TPS (U/L) | Serum zinc (μmol/L) | 8.8 | 0.28 (0.12–0.44) | 0.053 | 0.00078 |
| Ln of CA 125 (U/mL) | pg TEQ/g fat | 0.0042 | 0.19 (0.04–0.35) | 0.029 | 0.016 |
| Ln of CA 125 (U/mL) | Serum copper (μmol/L) | 0.022 | 0.16 (0.007–0.32) | 0.021 | 0.041 |
| Square root of c-erbB-2 (pmol/mL) | Serum copper (μmol/L) | −0.014 | −0.37 (−0.50 to −0.23) | 0.11 | < 0.0001 |
| Ln of IGF-I (ng/mL) | Serum copper (μmol/L) | −0.027 | −0.32 (−0.47 to −0.18) | 0.083 | < 0.0001 |
CI, confidence interval. A multiple regression was performed with each TAP as the dependent variable and with all 29 available personal, lifestyle, and internal exposure parameters as independent variables. When considering association with Iex, we performed a multiple regression with each TAP as the dependent variable and with Iex and all 21 available personal and lifestyle parameters as independent variables. Multiple regressions using as independent variables only age and the parameters (selected for each TAP through forward stepwise regression) showing the strongest association with the TAP used as the dependent variable gave similar results, with the same associations showing up as statistically significant (data not shown).
If correction for multiple testing is implemented, statistical significance requires p < 0.0063.